Lupus & antiphospholipid syndrome
Association of Elevated Serum S100A8 / A9 Levels and Cognitive Impairment in Patients With Systemic Lupus Erythematosus
Main finding · Serum S100A8/A9 levels (higher in CI)Result — go to the resultr 0.413Authors' conclusion
In this large cohort of patients with well-characterized SLE, serum S100A8/A9 levels were elevated in those with CI and showed an inverse relationship with cognitive performance across multiple domains. Changes in S100A8/A9 levels corresponded with changes in cognitive status over one year.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE)
- Participants
- 112 patients
- Exposure
- SLE with CI vs SLE without CI
- CIn = 48
- Outcome
- Serum S100A8/A9 levels in CI vs non-CI
- Follow-up
- Baseline and one year
Methodological details1-year follow-up
- 1-year follow-up
Main finding
Serum S100A8/A9 levels (higher in CI) · baseline
r
0.413
P = 0.0007
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | R | P value |
|---|---|---|
| Serum S100A8/A9 levels (higher in CI) · one year | 0.359 | P = 0.0045 |
- CI prevalence at baseline
- 42.8% · 48
Change in cognitive function after one year
- Stable
- 55%
- Improved
- 31.2%
- Worsened
- 13%
Change in S100A8/A9 by cognitive change · one year
- Worsened group showed a significant increase in S100A8/A9 levels
- Improved group exhibited a reduction
Original publication
Association of Elevated Serum S100A8 / A9 Levels and Cognitive Impairment in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). Published 11 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →